Search found 1665 matches

by biopearl123
Sun Dec 18, 2022 6:18 pm
Forum: ImetelChat
Topic: Everyone is a little edgy
Replies: 20
Views: 11135

Re: Everyone is a little edgy

I have a few more thoughts to share but won’t get to it until later tonight
by biopearl123
Sun Dec 18, 2022 6:59 am
Forum: ImetelChat
Topic: Everyone is a little edgy
Replies: 20
Views: 11135

Re: Everyone is a little edgy

Kmall, let’s start with the lymphoma study at MD Anderson. To better understand the history of the carrot, all one has to do is substitute the words Lane for Iyer and AML for lymphoma. Four years ago Dr. Scarlett held a conference that headlined Dr. Lane and his AML research. Very impressive mouse r...
by biopearl123
Sun Dec 18, 2022 4:01 am
Forum: ImetelChat
Topic: Everyone is a little edgy
Replies: 20
Views: 11135

Everyone is a little edgy

I could not help but notice that some regular and valued posters are a little edgy after ASH given the absence of a major PR program by Geron post presentations. The fact is, the clinical data to date, has been milked (with the exception of the new data on Luspatercept failures which was encouraging...
by biopearl123
Sat Dec 17, 2022 8:50 pm
Forum: ImetelChat
Topic: Yet more work for Kmall...
Replies: 10
Views: 3743

Re: Yet more work for Kmall...

You both make very valid points. There have been many false starts over the years. Many. Starting with a 2017 time line for a marketable drug. It’s all moot since we stayed in and followed closely and suffered many disappointments together. In a little over two weeks we will know if the emperor is a...
by biopearl123
Sat Dec 17, 2022 5:44 am
Forum: ImetelChat
Topic: Does anyone think this is a typo?
Replies: 5
Views: 1899

Does anyone think this is a typo?

“ This leader will manage the data lifecycle from strategy, acquisition, management, and governance in addition to identifying, driving prioritizing, and monitoring the successful development of a US Commercial Technology Ecosystem for all future Geron Hematology / Oncology portfolio products.”
by biopearl123
Fri Dec 16, 2022 11:48 pm
Forum: ImetelChat
Topic: Yet more work for Kmall...
Replies: 10
Views: 3743

Re: Yet more work for Kmall...

Kmall, thanks to your own efforts, many who read and contribute to this board have found a great deal of reassurance in reviewing the now 100 or so names and positions of highly qualified, experienced people in the pharma industry. I know I have. There is a lot of talent and overlap of skill sets, n...
by biopearl123
Fri Dec 16, 2022 11:36 pm
Forum: ImetelChat
Topic: More Ash 2022 - check out at 6 min 25 sec
Replies: 1
Views: 614

Re: More Ash 2022 - check out at 6 min 25 sec

Hat tip to Hunt. Very reassuring and valuable.
by biopearl123
Fri Dec 16, 2022 1:19 am
Forum: ImetelChat
Topic: Yet more work for Kmall...
Replies: 10
Views: 3743

Re: Yet more work for Kmall...

Aron shared that Olivia and team are covering until her return. Any concerns can be addressed via IR. Personally I am delighted that she has the confidence in herself as well as Geron having the confidence her to show support associated with important life events, especially those associated with lo...
by biopearl123
Wed Dec 14, 2022 3:14 am
Forum: ImetelChat
Topic: Yet more work for Kmall...
Replies: 10
Views: 3743

Yet more work for Kmall...

More postions posted on "Careers site" Geron home page.
by biopearl123
Wed Dec 14, 2022 2:46 am
Forum: ImetelChat
Topic: Potential Commercial Names for Imetelstat
Replies: 4
Views: 1457

Re: Potential Commercial Names for Imetelstat

Because we can't. If you are truly a "doctor real" you would know the FDA has strict naming requirements and Imetelstat is a generic name. But keep trying, you might come up with something great!! But we could call it "Imetelchat". :)
by biopearl123
Tue Dec 13, 2022 4:25 am
Forum: ImetelChat
Topic: A Glaring Omission (It’s not Geron’s—yet)
Replies: 6
Views: 1420

Re: A Glaring Omission (It’s not Geron’s—yet)

More on this. When Geron talked about Imetelstat having a highly differentiated profile from the competition, I attributed this to anticipated improved TI VAF etc, all the things we have talked about. But after reading Dr. Heyrman’s article and seeing the surprisingly lukewarm effect of luspatercept...
by biopearl123
Mon Dec 12, 2022 9:18 pm
Forum: ImetelChat
Topic: A Glaring Omission (It’s not Geron’s—yet)
Replies: 6
Views: 1420

Re: A Glaring Omission (It’s not Geron’s—yet)

From the clinical trial site: Part 2 (Main Study): Assessment of Functional Assessment of Cancer Therapy-Anemia-Related Effects (FACT-An) [ Time Frame: During study (approximately 2 years) ] The Functional Assessment of Cancer Therapy Anemia (FACT-An), is included in order to provide an assessment o...
by biopearl123
Mon Dec 12, 2022 9:10 pm
Forum: ImetelChat
Topic: A Glaring Omission (It’s not Geron’s—yet)
Replies: 6
Views: 1420

Re: A Glaring Omission (It’s not Geron’s)

From Dr. Hyerman’s opinion piece:

“ To the best of my knowledge, no HRQoL data were collected during this phase II study of imetelstat.”

While true for Part I of the IMerge trial it is front and center in Part II.
by biopearl123
Mon Dec 12, 2022 8:43 pm
Forum: ImetelChat
Topic: A Glaring Omission (It’s not Geron’s—yet)
Replies: 6
Views: 1420

A Glaring Omission (It’s not Geron’s—yet)

Reassuring to see the Luspatercept failures responding to Imetelstat. Assuming the PIII data reflects the PII data we should see recognition finally in Geron’s value in a few weeks. Imetelstat is distinguishing itself compared to ESA’s and Luspatercept. It is reasonable to expect that the IMerge PII...
by biopearl123
Sun Dec 11, 2022 3:52 pm
Forum: ImetelChat
Topic: Searching for Lazerus
Replies: 3
Views: 1298

Re: Searching for Lazerus

Laz has a distant cousin who follows this board closely . He may or may not choose to reveal himself. While we are on the subject, it would be wonderful to hear from CKTC and Sdraw as well.
by biopearl123
Sun Dec 11, 2022 6:52 am
Forum: ImetelChat
Topic: Could this be Geron’s secret?
Replies: 1
Views: 937

Could this be Geron’s secret?

I always thought that improvement in bone marrow fibrosis would correlate to improvement in OS. It was an assumption that seemed logical. It also probably as far as I can tell, drove the research that gave rise to such interest in BET inhibitors like pelabresib (Constellation Pharma acquired by Morp...